Pancreatic Cancer Clinical Trial
Official title:
POstopeRative Standardization of Care: THe Implementation of Best Practice After Pancreatic Resection. a Nationwide Stepped-Wedge Cluster Randomized Trial
This Nationwide stepped-wedge cluster randomized trial is designed to evaluate if the implementation of a best practice algorithm for postoperative care results in a decrease in incidence of major complications and death after pancreatic resection as compared to current practice.
Rationale
Pancreatic resection is a major abdominal operation with 50% chance of postoperative
complications. A feared complication is severe pancreatic fistula, in which there is leakage
of enzyme rich fluid into the abdominal cavity. Adequate complication management appears to
be the most important factor in improving outcomes of patients undergoing pancreatic
resection.
Objective
To investigate whether implementation of a best practice algorithm for postoperative care
focusing on early detection and step-up management of postoperative pancreatic fistula
results in a lower rate of major complications and death after pancreatic resection as
compared to current practice
Study design
A nationwide stepped-wedge, cluster randomized, superiority trial. In this design all
participating centers cross over from current practice to best practice according to the
algorithm, but are randomized to determine the exact order. At the end of the trial, all
centers will have implemented the best practice algorithm.
Study population
All centers performing pancreatic surgery in the Netherlands (i.e. the Dutch Pancreatic
Cancer Group).
Intervention
Cluster level education on postoperative care according to a best practice algorithm,
focusing on early detection and step-up management of postoperative pancreatic fistula. This
algorithm is based on findings in Dutch observational cohort studies, systematic literature
analyses, an inventory in current protocols on postoperative care and expert opinion. The
proposed algorithm is validated in a multicenter cohort and consensus upon this algorithm is
reached with pancreatic surgeons from all centers of the Dutch Pancreatic Cancer Group. The
final algorithm was reviewed critically by the advisory committee of internationally
respected experts in the field of pancreatology before implementation in this trial.
Comparison
Postoperative care according to current practice.
Endpoints
The primary outcome was measured in all patients undergoing pancreatic resection and is a
composite of major complications (i.e. postpancreatectomy bleeding, new-onset organ failure
and death). Secondary endpoints include the individual components of the primary endpoint and
other clinical outcomes, number of patients receiving adjuvant chemotherapy, healthcare
resource utilization and costs analysis. Follow-up will be 90 days after pancreatic
resection.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|